Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
about
Exercise as an Adjuvant Therapy for Hematopoietic Stem Cell MobilizationEfficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialA thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein productsStatistical Considerations in the Design of Biosimilar Cancer Clinical Trials.Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.The safety of switching between therapeutic proteins.Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Clinical experience with Zarzio® in Europe: what have we learned?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationTbo-Filgrastim: A Review in Neutropenic Conditions.Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months.Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers.Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.Biosimilar rhG-CSFs: how similar are they?Aerobic exercise in humans mobilizes HSCs in an intensity-dependent manner.Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers.First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factorSample Size for Multiple Hypothesis Testing in Biosimilar DevelopmentComparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
P2860
Q26749247-52530346-987F-428B-A49E-CED883903E25Q31085610-2B5E307E-ECEB-4C40-9CA3-A62DD0C076C3Q34013208-373F015B-7A99-483D-9027-43C3B44738D6Q35633293-2875F148-033B-4BC6-A4D3-9BE6A2E08755Q35835005-042CFD1B-8D4B-4E49-878E-551F99A3927BQ36411858-0147F11A-5226-4EB3-A50A-5AD525483452Q36951030-8491EE2A-BB7D-4A07-8D4E-526436E2F967Q36981948-029C831E-0AC6-4EE2-8E59-E1C25ED06A86Q37067591-1D8EF9C0-4591-4846-B5EC-67D211B0D105Q37616966-56D19C65-FF9F-4DE9-BF87-939C4C739227Q38030980-D82AE3FF-C5A1-4D26-AFC3-66DB2470DBEFQ38082542-31100504-3890-4860-B15F-69462849232AQ38125609-654548C3-E4D1-45CD-8788-196D2544C5D8Q38186025-7DA239DF-2B58-44E7-8420-B269BE976FA0Q38792513-7399A07C-0F56-48A8-9E77-5A064983D285Q38969947-0E1B8AB8-F478-45A4-9751-D3A2A35D060CQ39385304-9C4F6CF4-D9FE-4E00-A8D1-F0807BB3B48EQ42492546-811AB985-1AA5-4606-8419-A11E5F27AD86Q44555003-80619565-5B67-4DA4-BBE4-FC57CE9EEEB0Q44894394-6701A6DD-BBE3-471D-9851-4CE7A28D54D6Q45788056-DBEA7BA3-FA47-4D68-8AAB-E4ADC84E2777Q51048096-5ADF86F1-1D66-4333-8B67-80DDF0953BDBQ53379786-F5E891DF-1D89-4AF1-B73A-042483C88349Q57217646-D408962B-EEFD-4F11-A681-BFE3FA50037CQ57305837-5434CD80-E4DC-42E6-8972-96B03FE31222Q58806308-34B7A7D0-923A-4114-873D-2DF1F9BB9452
P2860
Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Pharmacokinetic and pharmacody ...... , randomized, crossover trial.
@en
Pharmacokinetic and pharmacody ...... , randomized, crossover trial.
@nl
type
label
Pharmacokinetic and pharmacody ...... , randomized, crossover trial.
@en
Pharmacokinetic and pharmacody ...... , randomized, crossover trial.
@nl
prefLabel
Pharmacokinetic and pharmacody ...... , randomized, crossover trial.
@en
Pharmacokinetic and pharmacody ...... , randomized, crossover trial.
@nl
P2093
P1433
P1476
Pharmacokinetic and pharmacody ...... , randomized, crossover trial.
@en
P2093
Anne-Katrin Maly
Heinz Lubenau
Kai Mehltretter
Karl Ernst Siegler
Peter Bias
P356
10.2165/00063030-200923010-00005
P577
2009-01-01T00:00:00Z
P6179
1020298355